Bharat Biotech International Ltd has initiated clinical trials for the Tuberculosis vaccine Mtbvac on adults in India. Developed by the Spanish biopharmaceutical company Biofabri, Mtbvac is the first TB vaccine derived from a human source. The vaccine aims to be more effective and longer-lasting than the current BCG vaccine for newborns and to prevent TB in adults and adolescents, for whom there is currently no effective vaccine. The trials are a significant step, especially in a country like India where 28% of the world s TB cases occur.
India Business News: HYDERABAD: The world’s first live attenuated vaccine of Mycobacterium tuberculosis isolated from a human, MTBVAC, developed by Spanish biopharma playe.
The only vaccine in use today BCG (Bacillus Calmette and Guerin) is an attenuated variant of the bovine TB pathogen. This is more than a hundred years old and has a limited effect on pulmonary tuberculosis, which is mostly responsible for the transmission of the disease. Studying the safety, immunogenicity and efficacy of MTBVAC in the most populated country in the world and the one with the highest number of cases of this infectious disease is key to continue advancing in this vaccine," the company said.
India News: HYDERABAD: Bharat Biotech, based in Hyderabad, has started clinical trials of MTBVAC, the world's first Mycobacterium tuberculosis vaccine derived fro.
A novel TB vaccine candidate that could replace the bacille Calmette-Guerin vaccine and has been found to provide significantly better protection against the TB germ in South African newborns, is set to reach a new benchmark in the new year as it will be tested on teenagers and adults with latent TB.